Neulasta Market Report 2026

Neulasta Market Overview

• The Neulasta market growth in the historic period has been driven by expansion of chemotherapy usage, rising incidence of treatment-induced neutropenia • Market expansion is supported by increasing demand for convenient drug delivery systems, rising investments in biosimilar competition • Growth Driver: Rising Cancer Incidence To Drive Market Growth • Market Trend: Innovative Drug Delivery Technologies In The Market • North America was the largest region in 2025.

What Is Covered Under Neulasta Market?

Neulasta is a prescription medication designed to reduce the risk of infection in chemotherapy patients by boosting white blood cell production. It is administered as an injection, often using an on-body injector or prefilled syringe, and is recognized for managing neutropenia efficiently and conveniently. The main indication types of neulasta are chemotherapy-induced neutropenia, bone marrow transplantation, and others. Chemotherapy-induced neutropenia is a condition where chemotherapy reduces neutrophil levels, a type of white blood cell crucial for fighting infections, increasing the risk of severe infections and complications during cancer treatment. The formulations are injectable solution and pre-filled syringes or pens and the distribution channel includes hospitals, oncology clinics, specialty pharmacies, and home healthcare services. It is used by various end users patients such as adult patients and pediatric patients.

What Is The Neulasta Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for convenient drug delivery systems, rising investments in biosimilar competition, expansion of home-based oncology treatments, growing focus on patient-centric cancer care, increasing adoption of long-acting biologics. Major trends in the forecast period include increasing adoption of long-acting neutropenia treatments, rising use of on-body injector systems, expansion of supportive oncology care, growing preference for outpatient cancer management, enhanced focus on treatment adherence.

Global Neulasta Market Segmentation

1) By Indication: Chemotherapy-Induced Neutropenia, Bone Marrow Transplantation, Other Indications 2) By Formulation: Injectable Solution, Pre-Filled Syringes Or Pens 3) By Distribution Channel: Hospitals, Oncology Clinics, Specialty Pharmacies, Home Healthcare Services 4) By End User Patients: Adult Patients, Pediatric Patients

What Are The Drivers Of The Neulasta Market?

The rising incidence of cancer is driving the growth of the neulasta market going forward. Cancer is a group of diseases characterized by abnormal cell growth, which can spread to other body parts. Cancer incidence is rising largely because populations are ageing, and the likelihood of developing cancer increases significantly as people live longer. Neulasta, a pegfilgrastim-based therapy, supports cancer care by preventing chemotherapy-induced neutropenia, stimulating white blood cell production, and reducing infection risks in patients undergoing chemotherapy. For instance, in August 2024, according to the Australian Institute of Health and Welfare, an Australia-based national agency for health statistics, Australia is projected to record approximately 209,000 new cancer cases by 2034, up from an estimated 169,000 cases in 2024, and cancer is expected to account for around three out of every ten deaths in 2024. Therefore, the rising incidence of cancer will drive the neulasta industry. The growing adoption of personalized medicine is expected to propel the growth of the neulasta market going forward. Personalized medicine involves tailoring treatments to individual patient profiles, enhancing efficacy, and reducing side effects. The adoption of personalized medicine is driven by advancements in genomics and biotechnology, enabling tailored treatments that improve effectiveness and minimize side effects, alongside increasing demand for precision in managing complex diseases such as cancer and rare genetic disorders. Neulasta (pegfilgrastim) supports personalized medicine by effectively preventing chemotherapy-induced neutropenia through precise dosing and advanced delivery systems such as autoinjectors, aligning treatment with individual patient needs and chemotherapy regimens. For instance, in February 2024, according to Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the Food and Drug Administration (FDA), a US-based federal agency under the Department of Health and Human Services, approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. The newly approved personalized treatments for 2023 include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing adoption of personalized medicine will drive the neulasta industry.

Key Players In The Global Neulasta Market

Major companies operating in the neulasta market are Amgen Inc.

Global Neulasta Market Trends and Insights

The key trend in the neulasta market is the development of drug delivery technologies, such as prefilled autoinjectors, to gain a competitive edge in the industry. Prefilled autoinjectors are self-injection devices preloaded with medication, designed for convenient and easy patient self-administration. For example, in March 2023, Coherus Biosciences, a US-based biopharmaceutical company, announced that the FDA approved a single-dose, prefilled autoinjector version of its pegfilgrastim biosimilar, Udenyca (pegfilgrastim-cbqv), for the treatment and prevention of febrile neutropenia, a common complication of chemotherapy. This autoinjector allows patients to receive pegfilgrastim the day after chemotherapy, reducing the risk of febrile neutropenia. The device features push-on-skin activation for reliable, immediate delivery of a full pegfilgrastim dose.

Regional Insights

North America was the largest region in the neulasta market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Neulasta Market?

The neulasta market consists of sales of prefilled syringes, injection devices, and biosimilar products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neulasta Market Report 2026?

The neulasta market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neulasta industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.